Can a Low-Dose Add-On drug lift depression and boost thinking in bipolar disorder?
NCT ID NCT04569448
First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether adding low-dose brexpiprazole to usual treatment can ease depressive episodes in people with bipolar I or II disorder. Researchers will measure changes in mood, thinking skills, and daily functioning over 8 weeks. The study enrolls adults aged 18 to 75 who have not responded to at least one other treatment for their current depression. The goal is to find a safe, easy-to-use option that helps both mood and cognition.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- brexpiprazole
- What this could lead to
- If it works, adding brexpiprazole could offer a safe, easy-to-use option that lifts depression and sharpens thinking in people with bipolar disorder.
- What could go wrong
- This is an open-label study, so both participants and researchers know the treatment, which can bias results. The trial is small and early, and brexpiprazole may cause side effects like restlessness or weight gain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 58 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2021
- Expected to finish
-
Dec 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Patient Inclusion Criteria: * Age: 18-75 * Male or female * Bipolar Disorder type I or type II * Current treatment-resistant depressive episode (with MADRS \>/= 24 and item 2 (reported sadness) \>/= 3) for a minimum of 2 weeks but \</= 52 weeks at screening visit and baseline visit * Patients must have failed at least one other treatment for the current depressive episode * If female and of childbearing potential, is using an adequate method of contraception. Adequate methods of contraception include abstinence; oral contraceptive pill or surgically implanted device; intra-uterine device; condom plus spermicidal foam or jelly; or tubal ligation * Is treated with a mood stabilizer (lithium and/or valproate and/or lamotrigine and/or quetiapine \</= 100mg/day) * The following laboratory values are within normal limits at Screening: CBC with differential; ferritin; extended electrolytes (sodium, potassium, chloride, calcium, magnesium, phosphate); thyroid function test(s); kidney function tests; hemoglobin A1c; lipid profile; prolactin * Normal EKG at Screening * Patient is able to give his(her) consent Patient Exclusion Criteria: * Is at high risk of suicide as defined by a score of \>/= 3 to item 10 of MADRS and/or in the clinical opinion of the investigator * Hypo(mania) episode with YMRS \>/= 8 * Psychotic symptoms as defined by a score of \>/= 4 to item 8 (content) of YMRS and/or in the opinion of the investigator * Is treated with fluoxetine OR carbamazepine * Is treated with risperidone OR olanzapine OR quetiapine \> 100mg/day OR ziprazidone OR any other antipsychotic * Is pregnant or lactating or absence of contraceptive treatment * Drug abuse or dependence as per DSM-V (MINI) * Unstable medical condition * Other unstable and/or untreated psychiatric condition, organic brain disorder, unstable and/or untreated medical condition such as hypothyroidism, hyperthyroidism, diabetes, cardiac condition, hypertension * Deficit in vitamin B12 or folate * Rapid cycling (more than 4 mood episodes per year) * Active or history of difficulty to swallow * Seizures not currently controlled with medications * Orthostatic hypotension defined as a drop in systolic blood pressure of at least 20 mmHg or of diastolic BP of at least 10 mmHg within 3 minutes of standing * A history of clinically significant cardiovascular disorders and cardiac arrhythmias * A low white blood cell count * Known eye disease * Involuntary, irregular muscle movements, especially in the face * Known hypersensitivity to Brexpiprazole and any components of its formulation * Known lactose intolerance or have hereditary galactose intolerance or glucose-galactose malabsorption, because Brexpiprazole and placebo tablets contain lactose (a disaccharide of glucose and galactose) * Active inflammatory disease including lupus, colitis, Crohn's disease, psoriasis, irritable bowel syndrome (IBS) * Mild or major neurocognitive disorder * Previous history of sensitivity/low tolerance to medications metabolized by CYP 2D6 inhibitors, or CYP 3A4 inducers Control Inclusion Criteria: * Age: 18-75 * Male or female * No current or past history of any psychiatric disorder * Patients must have failed at least one other treatment for the current depressive episode * If female and of childbearing potential, is using an adequate method of contraception. Adequate methods of contraception include abstinence; oral contraceptive pill or surgically implanted device; intra-uterine device; condom plus spermicidal foam or jelly; or tubal ligation * The following laboratory values are within normal limits at Screening: CBC with differential; ferritin; extended electrolytes (sodium, potassium, chloride, calcium, magnesium, phosphate); thyroid function test(s); kidney function tests; hemoglobin A1c; lipid profile; prolactin * Normal EKG at Screening * Patient is able to give his(her) consent Control Exclusion Criteria: * Alcohol or drug abuse * Deficit in vitamin B12 or folate * Seizures not currently controlled with medications * History of clinically significant cardiovascular disorders and cardiac arrhythmias * Mild or major neurocognitive disorder Patient/Control Exclusion Criteria for MRI: * Pacemaker * Heart/vascular clip * Metal prosthesis * Metal fragments in body * Transdermal patch * Aneurysm clip * Prosthetic valve * Claustrophobia * Pregnant
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bipolar depression are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Douglas Mental Health University Institute
RECRUITINGMontreal, Quebec, H4H 1R3, Canada
-
Jewish General Hospital
WITHDRAWNMontreal, Quebec, H3T 1E2, Canada
-
McMaster University
TERMINATEDHamilton, Ontario, L8S 4L8, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single psychedelic dose rewire the depressed brain?
- Can brain implants read and treat bipolar depression without triggering mania?
- Brain wave patterns and inflammation: a clue to ECT's effectiveness in older adults?
- Could a common antibiotic and supplement lift bipolar depression?
- Could a new pill ease bipolar depression in young people?
- Can a blood test predict who will respond to ketamine for depression?